Abstract
The prognosis for patients with advanced gastric cancer (AGC) remains poor, and systemic chemotherapy is the main treatment option. Many clinical studies utilizing oxaliplatin-based regimens as first-line treatment for AGC have been conducted by Chinese investigators. However, there is no clear consensus concerning the role of oxaliplatin in AGC in Chinese patients. The aim of the present literature-based meta-analysis was to compare the efficacy and tolerability of oxaliplatin-based regimens with cisplatin-based regimens in Chinese patients with AGC. The search period included trials published between January 2003 and October 2007. A total of 116 trials were identified, of which 104 trials were excluded, and 12 trials were included in this meta-analysis. The present meta-analysis showed that oxaliplatin-based regimens may be associated with higher 1-year survival and objective response rates in Chinese patients with AGC compared with cisplatin-based regimens. Cisplatin was more frequently associated with nausea/vomiting and anemia, while peripheral neuropathy, which resolved over time, was more common with oxaliplatin. High quality, large-scale, randomized, controlled phase III trials are needed to accurately identify the therapeutic effect of oxaliplatin in Chinese patients with AGC.
Keywords: Advanced gastric cancer, oxaliplatin, cisplatin, Chinese
Current Cancer Therapy Reviews
Title: The Role of Oxaliplatin-Based Versus Cisplatin-Based Regimens in Advanced Gastric Cancer: A Systematic Review and Pooled Analysis of the Chinese Literature
Volume: 6 Issue: 3
Author(s): Fenghua Wang, Fanggong Jiang, Yuhong Li, Ying Guo, Lin Shen and Li Zhang
Affiliation:
Keywords: Advanced gastric cancer, oxaliplatin, cisplatin, Chinese
Abstract: The prognosis for patients with advanced gastric cancer (AGC) remains poor, and systemic chemotherapy is the main treatment option. Many clinical studies utilizing oxaliplatin-based regimens as first-line treatment for AGC have been conducted by Chinese investigators. However, there is no clear consensus concerning the role of oxaliplatin in AGC in Chinese patients. The aim of the present literature-based meta-analysis was to compare the efficacy and tolerability of oxaliplatin-based regimens with cisplatin-based regimens in Chinese patients with AGC. The search period included trials published between January 2003 and October 2007. A total of 116 trials were identified, of which 104 trials were excluded, and 12 trials were included in this meta-analysis. The present meta-analysis showed that oxaliplatin-based regimens may be associated with higher 1-year survival and objective response rates in Chinese patients with AGC compared with cisplatin-based regimens. Cisplatin was more frequently associated with nausea/vomiting and anemia, while peripheral neuropathy, which resolved over time, was more common with oxaliplatin. High quality, large-scale, randomized, controlled phase III trials are needed to accurately identify the therapeutic effect of oxaliplatin in Chinese patients with AGC.
Export Options
About this article
Cite this article as:
Wang Fenghua, Jiang Fanggong, Li Yuhong, Guo Ying, Shen Lin and Zhang Li, The Role of Oxaliplatin-Based Versus Cisplatin-Based Regimens in Advanced Gastric Cancer: A Systematic Review and Pooled Analysis of the Chinese Literature, Current Cancer Therapy Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339410791698188
DOI https://dx.doi.org/10.2174/157339410791698188 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glucose Blood Levels as a Therapeutic Target in Acute Ischaemic Stroke Setting
Current Topics in Medicinal Chemistry Cancer Prevention by Dietary Bioactive Components that Target the Immune Response
Current Cancer Drug Targets Technetium Labeled Small Peptide Radiopharmaceuticals in the Identification of Lung Cancer
Current Pharmaceutical Design MicroRNA Mediated Network and DNA Methylation in Colorectal Cancer
Protein & Peptide Letters Mn-SOD and Chronic Inflammation of Gastric Mucosa
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer
Current Cancer Drug Targets Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Current Pharmaceutical Design Anti-Cancer Therapies that Utilize Cell Penetrating Peptides
Recent Patents on Anti-Cancer Drug Discovery Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges
Current Pharmaceutical Design The Role for Oxidative Stress in Aberrant DNA Methylation in Alzheimer’s Disease
Current Alzheimer Research microRNAs as Anti-Cancer Therapy
Current Pharmaceutical Design Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors
Current Pharmaceutical Design Extracellular Vesicles Isolated from Mesenchymal Stromal Cells Primed with Hypoxia: Novel Strategy in Regenerative Medicine
Current Stem Cell Research & Therapy Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Regulation of Bcl-2 Family Proteins by Posttranslational Modifications
Current Molecular Medicine MicroRNA: Biogenesis, Function and Role in Cancer
Current Genomics Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Mechanisms to Inhibit Matrix Metalloproteinase Activity: Where are we in the Development of Clinically Relevant Inhibitors?
Recent Patents on Anti-Cancer Drug Discovery Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers
Current Pharmaceutical Design